Suppr超能文献

治疗性无毒剂量的肿瘤坏死因子(TNF)可使肿瘤坏死因子受体2(TNFR2)-p75基因敲低的Lewis肺癌肿瘤移植物显著消退。

Therapeutic non-toxic doses of TNF induce significant regression in TNFR2-p75 knockdown Lewis lung carcinoma tumor implants.

作者信息

Sasi Sharath P, Bae Sanggyu, Song Jin, Perepletchikov Aleksandr, Schneider Douglas, Carrozza Joseph, Yan Xinhua, Kishore Raj, Enderling Heiko, Goukassian David A

机构信息

Cardiovascular Research Center, GeneSys Research Institute, Boston, Massachusetts, United States of America.

Cardiovascular Research Center, GeneSys Research Institute, Boston, Massachusetts, United States of America; Departments of Medicine and Pathology, Steward St. Elizabeth' Medical Center, Boston, Massachusetts, United States of America.

出版信息

PLoS One. 2014 Mar 24;9(3):e92373. doi: 10.1371/journal.pone.0092373. eCollection 2014.

Abstract

Tumor necrosis factor-alpha (TNF) binds to two receptors: TNFR1/p55-cytotoxic and TNFR2/p75-pro-survival. We have shown that tumor growth in p75 knockout (KO) mice was decreased more than 2-fold in Lewis lung carcinoma (LLCs). We hypothesized that selective blocking of TNFR2/p75 LLCs may sensitize them to TNF-induced apoptosis and affect the tumor growth. We implanted intact and p75 knockdown (KD)-LLCs (>90%, using shRNA) into wild type (WT) mice flanks. On day 8 post-inoculation, recombinant murine (rm) TNF-α (12.5 ng/gr of body weight) or saline was injected twice daily for 6 days. Tumor volumes (tV) were measured daily and tumor weights (tW) on day 15, when study was terminated due to large tumors in LLC+TNF group. Tubular bones, spleens and peripheral blood (PB) were examined to determine possible TNF toxicity. There was no significant difference in tV or tW between LLC minus (-) TNF and p75KD/LLC-TNF tumors. Compared to 3 control groups, p75KD/LLC+TNF showed >2-5-fold decreases in tV (p<0.001) and tW (p<0.0001). There was no difference in tV or tW end of study vs. before injections in p75KD/LLC+TNF group. In 3 other groups tV and tW were increased 2.7-4.5-fold (p<0.01, p<0.0002 and p<0.0001). Pathological examination revealed that 1/3 of p75KD/LLC+rmTNF tumors were 100% necrotic, the remaining revealed 40-60% necrosis. No toxicity was detected in bone marrow, spleen and peripheral blood. We concluded that blocking TNFR2/p75 in LLCs combined with intra-tumoral rmTNF injections inhibit LLC tumor growth. This could represent a novel and effective therapy against lung neoplasms and a new paradigm in cancer therapeutics.

摘要

肿瘤坏死因子-α(TNF)与两种受体结合:TNFR1/p55-细胞毒性受体和TNFR2/p75-促生存受体。我们已经表明,在Lewis肺癌(LLC)中,p75基因敲除(KO)小鼠的肿瘤生长减少了2倍以上。我们推测,选择性阻断TNFR2/p75 LLCs可能会使其对TNF诱导的凋亡敏感,并影响肿瘤生长。我们将完整的和p75基因敲低(KD)的LLCs(使用shRNA,敲低率>90%)植入野生型(WT)小鼠的侧腹。接种后第8天,每天两次注射重组鼠(rm)TNF-α(12.5 ng/克体重)或生理盐水,共6天。每天测量肿瘤体积(tV),并在第15天测量肿瘤重量(tW),此时由于LLC+TNF组肿瘤过大,研究终止。检查管状骨、脾脏和外周血(PB)以确定可能的TNF毒性。LLC减去(-)TNF组和p75KD/LLC-TNF组的tV或tW没有显著差异。与3个对照组相比,p75KD/LLC+TNF组的tV(p<0.001)和tW(p<0.0001)下降了2至5倍以上。在p75KD/LLC+TNF组中,研究结束时的tV或tW与注射前没有差异。在其他3组中,tV和tW增加了2.7至4.5倍(p<0.01、p<0.0002和p<0.0001)。病理检查显示,1/3 的p75KD/LLC+rmTNF肿瘤100%坏死,其余肿瘤坏死率为40-60%。在骨髓、脾脏和外周血中未检测到毒性。我们得出结论,阻断LLCs中的TNFR2/p75并结合瘤内注射rmTNF可抑制LLC肿瘤生长。这可能代表一种针对肺肿瘤新型且有效的治疗方法,也是癌症治疗的一种新范式。

相似文献

1
Therapeutic non-toxic doses of TNF induce significant regression in TNFR2-p75 knockdown Lewis lung carcinoma tumor implants.
PLoS One. 2014 Mar 24;9(3):e92373. doi: 10.1371/journal.pone.0092373. eCollection 2014.
2
Breaking the 'harmony' of TNF-α signaling for cancer treatment.
Oncogene. 2012 Sep 13;31(37):4117-27. doi: 10.1038/onc.2011.567. Epub 2011 Dec 12.
3
TNF-TNFR2/p75 signaling inhibits early and increases delayed nontargeted effects in bone marrow-derived endothelial progenitor cells.
J Biol Chem. 2014 May 16;289(20):14178-93. doi: 10.1074/jbc.M114.567743. Epub 2014 Apr 7.
9
Transmembrane tumor necrosis factor alpha attenuates pressure-overload cardiac hypertrophy via tumor necrosis factor receptor 2.
PLoS Biol. 2020 Dec 3;18(12):e3000967. doi: 10.1371/journal.pbio.3000967. eCollection 2020 Dec.
10
Tumor necrosis factor alpha (TNF-alpha) receptor-II is required for TNF-alpha-induced leukocyte-endothelial interaction in vivo.
Blood. 2007 Mar 1;109(5):1938-44. doi: 10.1182/blood-2006-05-020875. Epub 2006 Oct 26.

引用本文的文献

1
TNFR2 deficiency impairs the growth of mouse colon cancer.
Int J Biol Sci. 2023 Jan 22;19(4):1024-1035. doi: 10.7150/ijbs.72606. eCollection 2023.
2
TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy.
Med Oncol. 2022 Sep 29;39(12):215. doi: 10.1007/s12032-022-01772-2.
4
LyeTx I-b Peptide Attenuates Tumor Burden and Metastasis in a Mouse 4T1 Breast Cancer Model.
Antibiotics (Basel). 2021 Sep 21;10(9):1136. doi: 10.3390/antibiotics10091136.
5
TNFα and Immune Checkpoint Inhibition: Friend or Foe for Lung Cancer?
Int J Mol Sci. 2021 Aug 13;22(16):8691. doi: 10.3390/ijms22168691.
6
Dual Role of TNF and LTα in Carcinogenesis as Implicated by Studies in Mice.
Cancers (Basel). 2021 Apr 8;13(8):1775. doi: 10.3390/cancers13081775.
7
Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer.
Front Oncol. 2020 Apr 22;10:584. doi: 10.3389/fonc.2020.00584. eCollection 2020.
8
A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy.
J Oncol. 2019 May 23;2019:6313242. doi: 10.1155/2019/6313242. eCollection 2019.
10
TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors.
Front Immunol. 2018 May 28;9:1170. doi: 10.3389/fimmu.2018.01170. eCollection 2018.

本文引用的文献

1
Mechanisms of chemoresistance in cancer stem cells.
Clin Transl Med. 2013 Jan 17;2(1):3. doi: 10.1186/2001-1326-2-3.
2
The 7th lung cancer TNM classification and staging system: Review of the changes and implications.
World J Radiol. 2012 Apr 28;4(4):128-34. doi: 10.4329/wjr.v4.i4.128.
3
Breaking the 'harmony' of TNF-α signaling for cancer treatment.
Oncogene. 2012 Sep 13;31(37):4117-27. doi: 10.1038/onc.2011.567. Epub 2011 Dec 12.
4
Global cancer statistics.
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
5
TNF receptor 2 pathway: drug target for autoimmune diseases.
Nat Rev Drug Discov. 2010 Jun;9(6):482-93. doi: 10.1038/nrd3030. Epub 2010 May 21.
6
Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy.
Cancer Res. 2010 Feb 15;70(4):1534-43. doi: 10.1158/0008-5472.CAN-09-2995. Epub 2010 Feb 9.
7
Adaptive therapy.
Cancer Res. 2009 Jun 1;69(11):4894-903. doi: 10.1158/0008-5472.CAN-08-3658.
10
Novel treatments for cancer cachexia.
Expert Opin Investig Drugs. 2007 Aug;16(8):1241-53. doi: 10.1517/13543784.16.8.1241.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验